
|Videos|October 28, 2013
New Therapeutics in Gynecologic Cancer
Author(s)Russell J. Schilder, MD
Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.
Advertisement
Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses new therapeutics and their role in gynecologic cancers.
Clinical Pearls
- There has been a renaissance in immunology and researchers are using immunotherapies to “wake up” the immune system
- Newer therapies, such as antibodies against PD-1 and PD-L1 and enzyme inhibitors, change the microenvironment to allow the immune system to do its job and kill the cancer
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































